Immunic Adds Veteran Biopharma Leader to Board

Immunic ( (IMUX) ) has shared an announcement.

Immunic, Inc., a late-stage biotechnology company focused on oral therapies for neurologic diseases, has its lead candidate vidofludimus calcium in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026. The drug, which combines neuroprotective, anti-inflammatory and anti-viral mechanisms, has already demonstrated therapeutic activity in phase 2 trials in several forms of MS and other indications.

On March 31, 2026, Immunic announced the appointment of veteran biopharmaceutical executive Jon Congleton to its Board of Directors, effective March 27, 2026. The move brings extensive CNS and commercial expertise, including leadership in the U.S. launch and growth of Copaxone as a leading MS therapy, to support Immunic’s planned transition from a development-stage to a commercial-stage company as it advances pivotal trials of vidofludimus calcium.

The most recent analyst rating on (IMUX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.

Spark’s Take on IMUX Stock

According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.

The score is held down primarily by weak financial performance (no revenue, persistent losses, heavy cash burn, and negative equity). Technicals are supportive but look overbought, and valuation is constrained by losses and no dividend. Corporate events add a modest offset via strengthened near-term funding, though listing compliance risk remains a key concern.

To see Spark’s full report on IMUX stock, click here.

More about Immunic

Immunic, Inc. is a late-stage biotechnology company developing novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), in phase 3 trials for relapsing multiple sclerosis. The drug has shown activity in phase 2 studies across multiple forms of MS and other diseases, and Immunic is also advancing earlier-stage candidates IMU-856 and IMU-381 for neurodegenerative, chronic inflammatory and autoimmune conditions.

Vidofludimus calcium acts as a first-in-class Nurr1 activator providing neuroprotective effects, while also delivering anti-inflammatory and anti-viral activity through selective inhibition of DHODH. The company’s pipeline positions it to target a broad range of CNS and immune-related disorders, as it moves toward expected top-line phase 3 MS data by the end of 2026.

Average Trading Volume: 3,556,199

Technical Sentiment Signal: Buy

Current Market Cap: $134.4M

For an in-depth examination of IMUX stock, go to TipRanks’ Overview page.